Amarin Corporation
| Company type | Public |
|---|---|
| Nasdaq: AMRN | |
| Industry | Biotechnology |
| Founded | 1993 |
| Headquarters | Dublin, Ireland Bridgewater, New Jersey, US |
Key people |
|
| Products | Vascepa (AMR-101) |
| Revenue | $614.1 Million (2020) |
Number of employees | ~1000 |
| Website | amarincorp |
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.